Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Teva | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Teva

Generic sales slide under European business strategy

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Teva
 
4Q Revenues: $5.2 billion (-5%)

4Q Earnings: $694 million (+84%)

FY Revenues: $20.3 billion (flat)

FY Earnings: $3.0 billion (+142%)

Comments: Generic revenues were $2.5 billion in the quarter, down 8%. U.S. revenues were flat at $1.2 billion. European revenues were $759 million, down16%, with lower revenues in Germany, France and Spain. ROW revenues were $532 million, down 12%. API sales to third parties were $178 million, up 2%. Copaxone sales were $1.1 billion, down 2% in the quarter. Azilect sales were 108 million, up 10%. Treanda sales were up 28% to $226 million. ProAir sales were up 5% to $120 million. Women’s Health sales were down 14% to $115 million.Specialty Medicinesrevenue was 2.2 billion, up 1%. U.S. sales were $1.6 billion, up 6%. European revenues were $448 million, down 11%, and ROW revenues amounted to $167 million, down 2%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters